Sage Therapeutics Shares Slide Premarket After Dalzanemdor Fails Again

Dow Jones

2024-11-20

By Colin Kellaher

Sage Therapeutics shares tumbled in premarket trading Wednesday after the biopharmaceutical company threw in the towel on dalzanemdor following the drug candidate's latest study failure.

Sage shares, which closed Tuesday at $4.91, were recently down 26% to $3.62 in premarket trading.

The company on Wednesday said a Phase 2 study of dalzanemdor missed its goals in patients with cognitive impairment associated with the brain disorder Huntington's disease.

Based on these results, the company does not plan further development of dalzanemdor.

Sage earlier this year reported similar Phase 2 study failures of dalzanemdor in Alzheimer's and Parkinson's diseases, and the Cambridge, Mass., company last month slashed a third of its workforce.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

November 20, 2024 06:59 ET (11:59 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2484103192"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2484103192\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2484103192?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-20 19:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2484103192","market":"other","top_or_hot":-1,"title":"Sage Therapeutics Shares Slide Premarket After Dalzanemdor Fails Again","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/SAGE\">Sage Therapeutics</a> shares tumbled in premarket trading Wednesday after the biopharmaceutical company threw in the towel on dalzanemdor following the drug candidate's latest study failure. \n</p>\n<p>\n  Sage shares, which closed Tuesday at $4.91, were recently down 26% to $3.62 in premarket trading. \n</p>\n<p>\n  The company on Wednesday said a Phase 2 study of dalzanemdor missed its goals in patients with cognitive impairment associated with the brain disorder Huntington's disease. \n</p>\n<p>\n  Based on these results, the company does not plan further development of dalzanemdor. \n</p>\n<p>\n  Sage earlier this year reported similar Phase 2 study failures of dalzanemdor in Alzheimer's and Parkinson's diseases, and the Cambridge, Mass., company last month slashed a third of its workforce. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 20, 2024 06:59 ET (11:59 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sage Therapeutics Shares Slide Premarket After Dalzanemdor Fails Again</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSage Therapeutics Shares Slide Premarket After Dalzanemdor Fails Again\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-11-20 19:59</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/SAGE\">Sage Therapeutics</a> shares tumbled in premarket trading Wednesday after the biopharmaceutical company threw in the towel on dalzanemdor following the drug candidate's latest study failure. \n</p>\n<p>\n  Sage shares, which closed Tuesday at $4.91, were recently down 26% to $3.62 in premarket trading. \n</p>\n<p>\n  The company on Wednesday said a Phase 2 study of dalzanemdor missed its goals in patients with cognitive impairment associated with the brain disorder Huntington's disease. \n</p>\n<p>\n  Based on these results, the company does not plan further development of dalzanemdor. \n</p>\n<p>\n  Sage earlier this year reported similar Phase 2 study failures of dalzanemdor in Alzheimer's and Parkinson's diseases, and the Cambridge, Mass., company last month slashed a third of its workforce. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 20, 2024 06:59 ET (11:59 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2484103192","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484103192","pubTimestamp":1732103940,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Sage Therapeutics shares tumbled in premarket trading Wednesday after the biopharmaceutical company threw in the towel on dalzanemdor following the drug candidate's latest study failure.Sage shares, which closed Tuesday at $4.91, were recently down 26% to $3.62 in premarket trading.The company on Wednesday said a Phase 2 study of dalzanemdor missed its goals in patients with cognitive impairment associated with the brain disorder Huntington's disease.Based on these results, the company does not plan further development of dalzanemdor.Sage earlier this year reported similar Phase 2 study failures of dalzanemdor in Alzheimer's and Parkinson's diseases, and the Cambridge, Mass., company last month slashed a third of its workforce.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SAGE":"Sage Therapeutics"},"translate_title":"Dalzanemdor再次失败后，Sage Therapeutics股价盘前下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SAGE":1},"content_text":"By Colin Kellaher \n\n\n \n\n\nSage Therapeutics shares tumbled in premarket trading Wednesday after the biopharmaceutical company threw in the towel on dalzanemdor following the drug candidate's latest study failure. \n\n\n  Sage shares, which closed Tuesday at $4.91, were recently down 26% to $3.62 in premarket trading. \n\n\n  The company on Wednesday said a Phase 2 study of dalzanemdor missed its goals in patients with cognitive impairment associated with the brain disorder Huntington's disease. \n\n\n  Based on these results, the company does not plan further development of dalzanemdor. \n\n\n  Sage earlier this year reported similar Phase 2 study failures of dalzanemdor in Alzheimer's and Parkinson's diseases, and the Cambridge, Mass., company last month slashed a third of its workforce. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 20, 2024 06:59 ET (11:59 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}